Expand all sections

Canakinumab

Ilaris

Extended indication Afname cardiovasculair risico
Therapeutic value No judgement
Total cost 3,000,000,000.00

Product

Active substance Canakinumab
Domain Cardiovascular diseases
Main indication Cardiovascular diseases
Extended indication Afname cardiovasculair risico
Proprietary name Ilaris
Manufacturer Novartis
Route of administration Subcutaneous
Therapeutical formulation Injection
Budgetting framework Intermural (MSZ)

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
Submission date October 2017
Expected Registration January 2019
Orphan drug No

Therapeutic value

Current treatment options PCSK9 remmers
Therapeutic value No judgement
Duration of treatment continuous
Frequency of administration 4 times a year
References Ridker et al. AHJ October 2011, Volume 162, Issue 4, Pages 597–605.

Expected patient volume per year

Patient volume

< 60,000

Market share is generally not included unless otherwise stated.
References Fabrikant; www.volksgezondheidenzorg.info; Ridker. JACC 2016, vol 67, no 6, 2016, 712-23.
Additional remarks Fabrikant heeft max. patiëntvolume gebaseerd op circa 252.000 patienten in Nederland die een myocard infarct hebben doogemaakt, waarvan 25% een verhoogde biomarker hsCRP heeft (vereiste voor behandeling). De werkgroep geeft aan dat het percentage van 25% met een verhoogde biomarker hsCRP hoger ligt.

Expected cost per patient per year

Cost > 50,000.00
References Medicijnkosten.nl
Additional remarks Meerkosten. €11.660,00 per injectieflacon.

Potential total cost per year

Total cost

3,000,000,000.00

This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.